Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

Daiki Katagishi, Daisuke Yasuda, Kyoko Takahashi, Shigeo Nakamura, Tadahiko Mashino, Tomoyuki Ohe

Research output: Contribution to journalArticlepeer-review

Abstract

COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.

Original languageEnglish
Article number129121
JournalBioorganic and Medicinal Chemistry Letters
Volume80
DOIs
Publication statusPublished - 2023 Jan 15

Keywords

  • COVID-19
  • Fullerene
  • Main protease
  • SARS-CoV-2

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease'. Together they form a unique fingerprint.

Cite this